BRPI9713914B8 - - Google Patents

Info

Publication number
BRPI9713914B8
BRPI9713914B8 BR9713914A BR9713914A BRPI9713914B8 BR PI9713914 B8 BRPI9713914 B8 BR PI9713914B8 BR 9713914 A BR9713914 A BR 9713914A BR 9713914 A BR9713914 A BR 9713914A BR PI9713914 B8 BRPI9713914 B8 BR PI9713914B8
Authority
BR
Brazil
Application number
BR9713914A
Other languages
Portuguese (pt)
Other versions
BRPI9713914B1 (en
BR9713914A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9713914(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9713914A publication Critical patent/BR9713914A/en
Publication of BRPI9713914B1 publication Critical patent/BRPI9713914B1/en
Publication of BRPI9713914B8 publication Critical patent/BRPI9713914B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BRPI9713914-9A 1996-12-11 1997-12-09 COMPOSITION, USE OF THE SAME, AND, PHARMACEUTICAL COMPOSITION BRPI9713914B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/764640 1996-12-11
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor
PCT/EP1997/006850 WO1998025965A2 (en) 1996-12-11 1997-12-09 Peptides and compounds that bind to the thrombopoietin receptor

Publications (3)

Publication Number Publication Date
BR9713914A BR9713914A (en) 2000-02-29
BRPI9713914B1 BRPI9713914B1 (en) 2017-06-20
BRPI9713914B8 true BRPI9713914B8 (en) 2021-05-25

Family

ID=25071323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713914-9A BRPI9713914B1 (en) 1996-12-11 1997-12-09 COMPOSITION, USE OF THE SAME, AND, PHARMACEUTICAL COMPOSITION

Country Status (24)

Country Link
US (2) US5869451A (en)
EP (3) EP2336165A1 (en)
JP (1) JP4128225B2 (en)
KR (3) KR100679576B1 (en)
CN (1) CN100379760C (en)
AR (2) AR010752A1 (en)
AT (1) ATE420893T1 (en)
AU (1) AU725731B2 (en)
BR (1) BRPI9713914B1 (en)
CA (1) CA2274149C (en)
CO (1) CO5080768A1 (en)
DE (1) DE69739219D1 (en)
ES (1) ES2321038T3 (en)
HR (1) HRP970683B1 (en)
MA (1) MA26454A1 (en)
PA (1) PA8442601A1 (en)
PE (1) PE27599A1 (en)
SV (1) SV1997000104A (en)
TN (1) TNSN97201A1 (en)
TR (2) TR199901971T2 (en)
TW (1) TW515804B (en)
UY (1) UY24805A1 (en)
WO (1) WO1998025965A2 (en)
ZA (1) ZA9711045B (en)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
CN1966520B (en) * 1995-06-07 2012-07-11 葛兰素集团有限公司 Peptides and compounds that bind to a receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US20010016568A1 (en) 1997-10-31 2001-08-23 Juan I. Luengo Novel metal complexes
CA2308135A1 (en) * 1997-10-31 1999-05-14 John G. Gleason Novel metal complexes
US6211200B1 (en) 1997-10-31 2001-04-03 Smithkline Beecham Corporation Metal complexes
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
ME00238B (en) * 1998-10-23 2011-02-10 Kirin Amgen Inc Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU7604400A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
KR20020056923A (en) 1999-11-18 2002-07-10 코르바스 인터내셔날, 인코포레이티드 Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
CA2407956A1 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
WO2002046238A2 (en) * 2000-12-05 2002-06-13 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
KR20040011480A (en) 2001-03-22 2004-02-05 덴드레온 샌 디에고 엘엘씨 Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
KR20030096292A (en) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
WO2002092841A2 (en) 2001-05-14 2002-11-21 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7208594B2 (en) * 2002-06-29 2007-04-24 Aquanova Ag Isoflavone concentrates as well as methods for their production
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
US7851503B2 (en) 2002-08-14 2010-12-14 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7482427B2 (en) * 2002-08-20 2009-01-27 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
WO2004026332A1 (en) * 2002-09-18 2004-04-01 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP1638587A4 (en) 2003-02-14 2007-04-18 Univ Missouri Contraceptive methods and compositions related to proteasomal interference
EA010099B1 (en) * 2003-05-12 2008-06-30 Афимакс, Инк. Novel peptides that bind to the erythropoietin receptor and methods for use thereof
ES2323465T3 (en) * 2003-05-12 2009-07-16 Affymax, Inc. NOVELTY PEPTIDES THAT JOIN THE Erythropoietin Receptor.
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
CA2525399A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
US7601746B2 (en) * 2003-08-12 2009-10-13 Shionogi & Co., Ltd. Compounds exhibiting thrombopoietin receptor agonism
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
SI1675606T1 (en) * 2003-08-28 2017-07-31 Janssen Pharmaceuticals, Inc. Peptides and compounds that bind to thrombopoietin receptors
DE602004009710T2 (en) 2003-12-31 2008-08-07 F. Hoffmann-La Roche Ag METHOD OF PEPTIDE SYNTHESIS USING A REDUCED AMOUNT OF DETERGENT
US7414028B1 (en) * 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
MX2007000216A (en) * 2004-07-08 2007-03-15 Amgen Inc Therapeutic peptides.
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
MX2007003320A (en) * 2004-09-24 2007-05-18 Amgen Inc Modified fc molecules.
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US20090005292A1 (en) * 2004-11-11 2009-01-01 Affymax, Inc. Novel Peptides that Bind to the Erythropoietin Receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
MX2007006819A (en) 2004-12-08 2007-07-24 Nissan Chemical Ind Ltd 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators.
CA2590204C (en) 2004-12-14 2012-12-04 Nissan Chemical Industries, Ltd. Amide compounds and thrombopoietin receptor activators
EP1861417B1 (en) 2005-03-10 2013-05-15 BioNTech AG Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2648732A1 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (en) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5205967B2 (en) 2005-11-07 2013-06-05 日産化学工業株式会社 Hydrazide compounds and thrombopoietin receptor activators
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
CA2635498A1 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
ES2354954T3 (en) * 2006-03-22 2011-03-21 Viral Logic Systems Technology Corp. METHODS FOR IDENTIFYING POLYPEPTIDE DIANS.
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
WO2007133811A2 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
JP5157900B2 (en) 2006-06-07 2013-03-06 日産化学工業株式会社 Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
WO2007150053A2 (en) 2006-06-22 2007-12-27 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
US8106154B2 (en) * 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
US20090054332A1 (en) * 2007-06-21 2009-02-26 Conjuchem Biotechnologies, Inc. Thombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (en) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 Bicycle substituted pyrazolone azo derivative, preparation thereof and use in medicine
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
EP2620448A1 (en) 2008-05-01 2013-07-31 Amgen Inc. Anti-hepcidin antibodies and methods of use
MX2011009797A (en) 2009-03-20 2012-01-12 Amgen Inc Selective and potent peptide inhibitors of kv1.3.
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
JP5704073B2 (en) 2009-10-23 2015-04-22 日産化学工業株式会社 Fused ring heterocyclic compounds and thrombopoietin receptor activators
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US10538555B2 (en) 2014-09-11 2020-01-21 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
RU2758608C2 (en) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Diagnostics method using hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
EP3827849A1 (en) 2016-05-19 2021-06-02 Bristol-Myers Squibb Company Pet-imaging immunomodulators
WO2018085750A2 (en) 2016-11-07 2018-05-11 Bristol-Myers Squibb Company Immunomodulators
CN110997698B (en) 2017-06-23 2023-12-26 百时美施贵宝公司 Immunomodulatory agents acting as PD-1 antagonists
JP2020528903A (en) * 2017-07-26 2020-10-01 ヤンセン ファーマシューティカ エヌ．ベー． How to Protect Targeted Radiation Therapy-Induced Vascular Integrity
CN111051332A (en) 2017-10-03 2020-04-21 百时美施贵宝公司 Immunomodulator
CA3127455A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
WO2020209920A2 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
MA54821A (en) 2019-01-25 2021-12-01 Janssen Pharmaceutica Nv METHODS FOR INCREASING PROTECTION AGAINST ORGAN AND VESSEL DAMAGE, HEMATOPOIETIC RECOVERY AND SURVIVAL IN RESPONSE TO EXPOSURE TO WHOLE BODY IRRADIATION OR CHEMICAL AGENTS
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (en) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Day and date setting device for clocks with calendar
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (en) * 1990-04-02 1994-01-10 Eniricerche Spa IMMUNOGENIC COMPOUNDS, THE PROCEDURE FOR THEIR SYNTHESIS AND THEIR USE FOR THE PREPARATION OF ANIMALARY VACCINES
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0644771B2 (en) * 1992-06-11 2006-12-06 Alkermes Controlled Therapeutics, Inc. Erythropoietin drug delivery system
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc Method for producing a highly enriched population of hematopoietic stem cells
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) * 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021626A1 (en) * 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0668352A1 (en) * 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
AU691828B2 (en) * 1994-02-14 1998-05-28 University Of Washington Hematopoietic protein and materials and methods for making it
EP0755263A4 (en) * 1994-03-31 2005-02-09 Amgen Inc Compositions and methods for stimulating megakaryocyte growth and differentiation
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
AU4163196A (en) * 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU705064B2 (en) * 1995-04-26 1999-05-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptides
CN1966520B (en) * 1995-06-07 2012-07-11 葛兰素集团有限公司 Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
KR102127408B1 (en) 2014-01-29 2020-06-29 삼성전자주식회사 Anti-Her3 scFv fragment and Bispecific anti-c-Met/anti-Her3 antibodies comprising the same

Also Published As

Publication number Publication date
BRPI9713914B1 (en) 2017-06-20
ES2321038T3 (en) 2009-06-01
EP0948539A2 (en) 1999-10-13
HRP970683B1 (en) 2002-10-31
US5869451A (en) 1999-02-09
PE27599A1 (en) 1999-03-29
AU5854798A (en) 1998-07-03
KR20000069408A (en) 2000-11-25
US6121238A (en) 2000-09-19
WO1998025965A3 (en) 1998-08-13
HRP970683A2 (en) 1998-10-31
CN1245504A (en) 2000-02-23
TR200401638T2 (en) 2004-11-22
KR100668546B1 (en) 2007-01-16
CA2274149A1 (en) 1998-06-18
AU725731B2 (en) 2000-10-19
JP2001505898A (en) 2001-05-08
KR100679576B1 (en) 2007-02-07
AR062931A2 (en) 2008-12-17
CN100379760C (en) 2008-04-09
TW515804B (en) 2003-01-01
CO5080768A1 (en) 2001-09-25
MA26454A1 (en) 2004-12-20
CA2274149C (en) 2008-07-15
UY24805A1 (en) 2000-12-29
BR9713914A (en) 2000-02-29
AR010752A1 (en) 2000-07-12
DE69739219D1 (en) 2009-03-05
KR20060025611A (en) 2006-03-21
KR20050042505A (en) 2005-05-09
EP2028191A1 (en) 2009-02-25
WO1998025965A2 (en) 1998-06-18
SV1997000104A (en) 1998-09-18
TNSN97201A1 (en) 2005-03-15
KR100625708B1 (en) 2006-09-20
JP4128225B2 (en) 2008-07-30
EP2336165A1 (en) 2011-06-22
TR199901971T2 (en) 1999-12-21
ZA9711045B (en) 1999-06-09
PA8442601A1 (en) 2000-05-24
ATE420893T1 (en) 2009-01-15
EP0948539B1 (en) 2009-01-14

Similar Documents

Publication Publication Date Title
DE69738826D1 (en)
DE69739573D1 (en)
CY2619B2 (en)
AR026659A2 (en)
BRPI9713914B8 (en)
DE69738566D1 (en)
DE69738765D1 (en)
DK1396A (en)
DK172494B1 (en)
DE69739765D1 (en)
ECSDI960307S (en)
ECSDI960315S (en)
BR9603859A (en)
DK79696A (en)
ECSDI960332S (en)
ECSDI960298S (en)
ECSDI960299S (en)
ECSDI960330S (en)
ECSDI960303S (en)
ECSDI960304S (en)
ECSDI960306S (en)
BR7600721U (en)
ECSDI960308S (en)
ECSDI960309S (en)
ECSDI960310S (en)

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/1997 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 09/12/2017